In this sense, lipid pathways involved in DHA acylation, and deacylation could constitute a promising strategy for new therapeutic approaches in synucleinopathies (see section “α-Synuclein and Lipid Signaling”) (Figure 1, 3). This evidence concerns the gene SNCA and synucleinopathy.